{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T01:04:16Z","timestamp":1784941456027,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007710","name":"University of Connecticut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msard.2020.102731","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T01:05:24Z","timestamp":1609635924000},"page":"102731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab"],"prefix":"10.1016","volume":"48","author":[{"given":"Nicholas","family":"Haberli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-5729","authenticated-orcid":false,"given":"Hamza","family":"Coban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-1038","authenticated-orcid":false,"given":"Charanpreet","family":"Padam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8391-1242","authenticated-orcid":false,"given":"Jairo M.","family":"Montezuma-Rusca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A.","family":"Creed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Imitola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2020.102731_bib0001","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.10148","article-title":"Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses","volume":"51","author":"Beck","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.msard.2020.102731_bib0002","unstructured":"CDC. Babesiosis (Babesia spp.) 2011 case definition. 2011 [cited 2020 June 21]; Available from: https:\/\/wwwn.cdc.gov\/nndss\/conditions\/babesiosis\/case-definition\/2011\/."},{"key":"10.1016\/j.msard.2020.102731_bib0003","unstructured":"CDC. Preventing Tick Bites. 2020 [cited 2020 November 14, 2020]; Available from: https:\/\/www.cdc.gov\/ticks\/avoid\/on_people.html."},{"issue":"9268","key":"10.1016\/j.msard.2020.102731_bib0004","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.msard.2020.102731_bib0005","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1002\/1097-0142(20011201)92:11<2927::AID-CNCR10109>3.0.CO;2-W","article-title":"Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients","volume":"92","author":"Dai","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.msard.2020.102731_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.msard.2020.102731_bib0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/clinids\/22.5.809","article-title":"Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin","volume":"22","author":"Falagas","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.msard.2020.102731_bib0008","unstructured":"FDA. FDA Adverse Events Reporting System (FAERS) Public Dashboard. 2020 [cited 2020 August 22]; Available from: https:\/\/fis.fda.gov\/sense\/app\/d10be6bb-494e-4cd2-82e4-0135608ddc13\/sheet\/8eef7d83-7945-4091-b349-e5c41ed49f99\/state\/analysis."},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0009","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102731_bib0010","first-page":"104","article-title":"[Babesiosis in an immunocompromised German patient]","volume":"103","author":"Haselbarth","year":"2008","journal-title":"Med Klin (Munich)"},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0011","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.msard.2020.102731_bib0012","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijpara.2008.03.001","article-title":"Babesiosis: recent insights into an ancient disease","volume":"38","author":"Hunfeld","year":"2008","journal-title":"Int J Parasitol"},{"issue":"9585","key":"10.1016\/j.msard.2020.102731_bib0013","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.msard.2020.102731_bib0014","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1212\/WNL.0000000000003078","article-title":"The 11-year long-term follow-up study from the randomized BENEFIT CIS trial","volume":"87","author":"Kappos","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102731_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.msard.2020.102731_bib0016","first-page":"855","article-title":"Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab","volume":"56","author":"Knight","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0017","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/525852","article-title":"Persistent and relapsing babesiosis in immunocompromised patients","volume":"46","author":"Krause","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.msard.2020.102731_bib0018","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2020.102731_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"issue":"10","key":"10.1016\/j.msard.2020.102731_bib0020","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/acr.22345","article-title":"Pancytopenia and cough in a man with amyopathic dermatomyositis","volume":"66","author":"Mecchella","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.msard.2020.102731_bib0022","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s002770100346","article-title":"Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report","volume":"80","author":"Ng","year":"2001","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.msard.2020.102731_bib0023","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diagmicrobio.2016.02.016","article-title":"Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis","volume":"85","author":"Raffalli","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.msard.2020.102731_bib0024","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamainternmed.2013.374","article-title":"Cerebral toxoplasmosis after rituximab therapy","volume":"173","author":"Safa","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.msard.2020.102731_bib0025","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/cid\/cix477","article-title":"Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia","volume":"65","author":"Simon","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.msard.2020.102731_bib0026","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/sj.leu.2402567","article-title":"Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge","volume":"16","author":"Skrabs","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.msard.2020.102731_bib0027","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1749-6632.1994.tb19865.x","article-title":"The emergence of Lyme disease and human babesiosis in a changing environment","volume":"740","author":"Spielman","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1016\/j.msard.2020.102731_bib0028","doi-asserted-by":"crossref","first-page":"ofx204","DOI":"10.1093\/ofid\/ofx204","article-title":"Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention","volume":"4","author":"Steininger","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.msard.2020.102731_bib0029","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.it.2011.09.001","article-title":"Staying alive: regulation of plasma cell survival","volume":"32","author":"Tangye","year":"2011","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ttbdis.2015.03.001","article-title":"Utilization of a real-time PCR assay for diagnosis of Babesia microti infection in clinical practice","volume":"6","author":"Wang","year":"2015","journal-title":"Ticks Tick Borne Dis"},{"issue":"3","key":"10.1016\/j.msard.2020.102731_bib0031","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/649859","article-title":"Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection","volume":"50","author":"Wormser","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.msard.2020.102731_bib0032","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1182\/bloodadvances.2018026468","article-title":"Robust adaptive immune response against Babesia microti infection marked by low parasitemia in a murine model of sickle cell disease","volume":"2","author":"Yi","year":"2018","journal-title":"Blood Adv"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820308051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820308051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:53:32Z","timestamp":1761900812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820308051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"alternative-id":["S2211034820308051"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102731","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102731"}}